MUC-1

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
목요일, 2월 29, 2024
Research, Smallpox, GeoVax, Matrix (biology), Neoplasm, Vaccine, Virus-like particle, ABL, COVID-19, Biotechnology, NIH, Hospital, Security (finance), Congress, Immunity, CGMP, DNA, Therapy, Pfizer, Acute leukemia, AACR, MUC-1, Conference, Vaccination, Safety, Chronic lymphocytic leukemia, Antigen, Patent, Clinical trial, Infection, MVA, SARS-CoV-2, Messenger, Cancer, CLL, Immunodeficiency, Risk, VP40, Death, Patient, HIV, Travel

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

GeoVax Announces Multiple Patent Issuances and Allowances

Retrieved on: 
화요일, 2월 13, 2024
COVID-19, Biotechnology, GeoVax, Matrix (biology), FDA, Cancer, Patent, MUC-1, Vaccine, VP40, Neoplasm, Data, Vaccination, Virus-like particle, Antigen, Intellectual property, Infection, MVA, HIV, DNA

ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.

Key Points: 
  • The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the allowance of the Company’s Patent Application No.
  • The U.S. Patent and Trademark Office issued Patent No.
  • 11,896,657 to GeoVax, pursuant to the Company’s patent application No.
  • David Dodd, GeoVax President and CEO, commented, “These patent actions add to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.

ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies

Retrieved on: 
목요일, 1월 6, 2022
Data Management, Manufacturing, Technology, Finance, Stem Cells, Pharmaceutical, Oncology, Professional Services, Clinical Trials, Other Manufacturing, Science, Biotechnology, Other Science, Health, Research, GMP, TRAIL, Therapy, Engineering, Program, WEHI, MUC-1, CISH, Gene editing, Company, Research, Patient, PD-1, IND, NSCLC, Tumor microenvironment, Cancer, Lymphatic system, CD38, JLab Audio, Disease, MD, AML, Neoplasm, Cryopreservation, DR4, Patent, TIGIT, NUI Galway, NK, CAR, TNF, Medical research, DR5, CD96, Pharmaceutical industry, Vaccine, Fine chemical, Medical imaging, Antibiotics, Fertilizer, Ovary, Breast

ONK will also continue progress towards a GMP manufacturing capability, as it optimizes both its proprietary cell engineering platform and process development.

Key Points: 
  • ONK will also continue progress towards a GMP manufacturing capability, as it optimizes both its proprietary cell engineering platform and process development.
  • The Company is pioneering optimally engineered natural killer (NK) cell therapies, utilising a suite of engineering strategies to optimize cytotoxic potential, metabolic health and persistence of NK cells, while reducing the potential for their exhaustion in the tumor microenvironment.
  • ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both hematological malignancies and solid tumors.
  • ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.